blog

NOVOS Core Trial Reports Changes in Three Vascular Measures

A small NOVOS Core trial reported changes in vascular markers. Understand the results, study limits and implications for active adults over 40.

NOVOS Core Trial Reports Changes in Three Vascular Measures
Share
White Reddit alien mascot face icon on transparent background.White paper airplane icon on transparent background.White stylized X logo on black background, representing the brand X/Twitter.
Nov 10, 2026
Longevity & Living Well

On November 3, 2026, research published in European Heart Journal Open reported favorable changes in three vascular measurements among apparently healthy adults over 40 assigned to NOVOS Core. The multi-ingredient supplement from NOVOS Labs was tested in the randomized STAMINA trial. If your priorities include mountain holidays and maintaining physical independence, the findings deserve attention without becoming another obligation in your routine.

The researchers reported differences favoring the supplement after six months for flow-mediated dilation, pulse wave velocity and systolic blood pressure. For an active reader considering longevity products, the useful question is how closely those measurements match the benefits you actually want.

The trial measured how blood vessels responded

The study’s primary outcome was flow-mediated dilation, usually shortened to FMD. This is an ultrasound measurement of how the brachial artery widens in response to increased blood flow.

In plain language, the researchers assessed an artery’s response to a change in blood flow. That is a specific measurement of vascular function. It gives the result a clearer meaning than a broad claim that a supplement supports healthy aging.

The distinction matters when reading product research. A study can report a favorable change in a defined measurement without answering every question suggested by the product’s positioning. Keeping the actual endpoint in view makes the evidence easier to assess.

Three reported differences favored NOVOS Core

According to the STAMINA paper in European Heart Journal Open, the six-month analysis found these adjusted between-group differences favoring the supplement:

  • Flow-mediated dilation: 2.9 percentage points.
  • Pulse wave velocity, reported as PWV: 1.18 m/s.
  • Systolic blood pressure: 6.1 mmHg.

These figures describe comparisons between the study groups after the researchers’ statistical adjustments. They should be read as study results rather than as a forecast of what an individual will experience.

FMD was the primary outcome, so it deserves particular attention when interpreting the paper. The other vascular measurements add context to that result. Taken together, they explain why the study attracted interest as a product-specific cardiovascular investigation.

The findings were not uniformly favorable across every measurement. The paper reported no statistically significant between-group differences in the measured cholesterol and triglyceride levels. A fair account therefore describes the vascular findings specifically rather than presenting the trial as evidence of improvement across cardiovascular health generally.

The evidence remains preliminary and product-specific

The paper reports that 61 adults were randomized and 43 completed both study visits. Its main six-month analysis used those 43 completers. This was a single-centre study, so the conclusion rests on a limited group of participants rather than a broad research programme.

The participants were apparently healthy adults over 40. The authors identify people with cardiovascular disease and other higher-risk conditions as outside the population to which the findings can readily be generalized. That boundary is particularly important when a reader’s interest in the product is connected to an existing health concern.

The authors describe the findings as preliminary. The trial was not powered to determine whether the reported changes translate into fewer clinical cardiovascular events. It also does not establish that NOVOS Core extends human lifespan.

The tested intervention was a multi-ingredient powder. Because the study assessed the formulation as a whole, it cannot identify which ingredient or combination accounted for the reported changes. The findings should not be transferred to an individual ingredient or a different supplement formula.

The researchers monitored adverse events. However, the trial’s small size and six-month duration do not establish long-term safety or outcomes. That is a separate question from whether the measured vascular differences were favorable.

The commercial relationship also belongs in the assessment. The paper reports that NOVOS Labs supplied the study product and control and made an unrestricted research contribution. It states that the funder had no role in specified research and publication decisions and discloses that one author worked for the company.

Those disclosures do not by themselves settle the quality of the findings. They are relevant context when deciding how much confidence to place in product-specific research. Independent replication and longer-term studies with clinical outcomes are needed before drawing broader conclusions.

The study leader described the findings as encouraging

In a University of Surrey news release, study lead Professor Christian Heiss called the results “encouraging clinical evidence.” The university’s account said he highlighted improvements across three measures of cardiovascular function.

That wording captures the scientific interest in the results. It is the lead researcher’s interpretation of the trial rather than a separate finding or a recommendation that everyone over 40 take the product.

For readers accustomed to confident supplement headlines, the useful approach is to keep the expert’s enthusiasm attached to the measurements he was discussing. The quote adds perspective, but the paper’s methods and results remain the foundation for judging the evidence.

Travel and sport require evidence tied to capability

The practical relevance becomes clearer when you name the benefit you want. Recovering well after a long journey is one question. Adjusting to altitude is another. Maintaining energy through a day of skiing or hiking is a third.

STAMINA did not establish that NOVOS Core improves any of those experiences. Its reported vascular measurements should therefore not be treated as evidence of better travel recovery, altitude adjustment or sustained sporting energy.

For trip planning, the sensible response is to keep this result separate from decisions about how demanding an itinerary should be. A favorable supplement study is not a reason to schedule a harder mountain day or assume that less recovery time will be sufficient. The news changes the evidence available about the product, not the demands of the trip.

The same distinction applies to sport. If your interest is maintaining muscle strength and stamina, look for research that measures those outcomes directly. A vascular endpoint and a performance endpoint answer different questions even when both appear in discussions of healthy aging.

This is also a useful principle when reading about practical measures of physical capacity. Start with the ability you want to preserve, then ask how closely the research measures it. That keeps the focus on capability rather than on collecting favorable laboratory results.

For someone considering NOVOS Core, one realistic next step is a focused conversation with a qualified health professional. That is particularly relevant when managing a health condition or treatment. The discussion can centre on the exact formulation studied and the personal reason for considering it.

There is no need to turn that decision into a complete review of every supplement on the shelf. Keep the question narrow: does this particular evidence justify considering this particular product for your circumstances? That approach gives the study appropriate attention without allowing a commercial longevity category to dictate your routine.

The trial is worth following because it reports defined results rather than relying only on broad promises. Its immediate practical value is as information for a selective decision, not as a new foundation for an active life.

Selectivity is the practical response

For the informed active adult, the sensible adjustment is to treat STAMINA as preliminary information for a qualified supplement discussion rather than a reason to change travel or training routines.

Sources

  1. Targeting multiple ageing-related processes with nutritional supplement shows promising effects on vascular health biomarkers
  2. Acute and 6-month vascular effects of a multi-component nutritional ...

Stay connected for research and practical guidance on longevity, strength, recovery, energy and active living. New ideas to help you stay capable, curious and ready for more.

White stylized X logo on black background, representing the brand X/Twitter.

Continue reading

November 22, 2026
Longevity & Living Well

Fitness Deserves a Bigger Place in Your Longevity Plans

read article
November 21, 2026
Longevity & Living Well

Later-Born Generations Show a Double Advantage in Memory

read article
November 20, 2026
Longevity & Living Well

The Capabilities That Make a Long Life Your Own

read article
start here

Stay ready for what comes next

Explore practical guidance on strength, recovery, energy, travel and longevity for a life that stays active.

explore the Blog